

Rob Glynn-Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5622285/publications.pdf>

Version: 2024-02-01

172
papers

12,198
citations

41344

49
h-index

26613

107
g-index

180
all docs

180
docs citations

180
times ranked

10486
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. <i>Lancet Oncology</i> , The, 2010, 11, 835-844.	10.7	1,532
2	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. <i>Annals of Oncology</i> , 2012, 23, 2479-2516.	1.2	1,233
3	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv22-iv40.	1.2	1,126
4	Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2Ã—2 factorial trial. <i>Lancet Oncology</i> , The, 2013, 14, 516-524.	10.7	580
5	Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. <i>Lancet Oncology</i> , The, 2015, 16, 200-207.	10.7	461
6	Prognostic Value of Pathologic Complete Response After Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 99-107.	0.8	396
7	Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). <i>British Journal of Cancer</i> , 2010, 102, 1123-1128.	6.4	348
8	Treatment of colorectal cancer in older patients: International Society of Geriatric Oncology (SIOG) consensus recommendations 2013. <i>Annals of Oncology</i> , 2015, 26, 463-476.	1.2	327
9	Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. <i>Annals of Oncology</i> , 2014, 25, 1356-1362.	1.2	247
10	Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii10-iii20.	1.2	244
11	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1165-1176.	1.0	237
12	Critical appraisal of the "wait and see" approach in rectal cancer for clinical complete responders after chemoradiation. <i>British Journal of Surgery</i> , 2012, 99, 897-909.	0.3	220
13	Influence of body composition profile on outcomes following colorectal cancer surgery. <i>British Journal of Surgery</i> , 2016, 103, 572-580.	0.3	208
14	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014, 111, 330-339.	0.6	179
15	Complete Clinical Response After Preoperative Chemoradiation in Rectal Cancer: Is a "Wait and See" Policy Justified?. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 10-20.	1.3	150
16	Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. <i>Annals of Oncology</i> , 2010, 21, 1743-1750.	1.2	141
17	Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 347-356.	10.7	132
18	Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?. <i>International Journal of Colorectal Disease</i> , 2006, 21, 11-17.	2.2	127

#	ARTICLE	IF	CITATIONS
19	Development and external validation of a nomogram and online tool to predict bowel dysfunction following restorative rectal cancer resection: the POLARS score. <i>Gut</i> , 2018, 67, gutjnl-2016-312695.	12.1	127
20	EXTRA—A Multicenter Phase II Study of Chemoradiation Using a 5 Day per Week Oral Regimen of Capecitabine and Intravenous Mitomycin C in Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 119-126.	0.8	120
21	Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. <i>British Journal of Surgery</i> , 2008, 95, 1534-1540.	0.3	109
22	Reirradiation of locally recurrent rectal cancer: A systematic review. <i>Radiotherapy and Oncology</i> , 2014, 113, 151-157.	0.6	102
23	Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 745-752.	0.8	99
24	Definition of the Rectum. <i>Annals of Surgery</i> , 2019, 270, 955-959.	4.2	96
25	Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?. <i>British Journal of Cancer</i> , 2006, 94, 363-371.	6.4	95
26	Adjuvant chemotherapy in rectal cancer: Defining subgroups who may benefit after neoadjuvant chemoradiation and resection: A pooled analysis of 3,313 patients. <i>International Journal of Cancer</i> , 2015, 137, 212-220.	5.1	94
27	International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 805-816.	27.6	93
28	Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancer. <i>Lancet Oncology</i> , The, 2017, 18, e354-e363.	10.7	89
29	Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2010, 21, v87-v92.	1.2	86
30	Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy?. <i>Acta Oncologica</i> , 2010, 49, 378-381.	1.8	85
31	Is it worth the wait? A survey of patients' satisfaction with an oncology outpatient clinic. <i>European Journal of Cancer Care</i> , 1997, 6, 50-58.	1.5	82
32	Alternative clinical end points in rectal cancer—are we getting closer?. <i>Annals of Oncology</i> , 2006, 17, 1239-1248.	1.2	82
33	The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. <i>Colorectal Disease</i> , 2006, 8, 800-807.	1.4	78
34	Prognostic factors for recurrence and survival in anal cancer. <i>Cancer</i> , 2013, 119, 748-755.	4.1	78
35	A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. <i>Annals of Oncology</i> , 2006, 17, 50-56.	1.2	75
36	The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?. <i>Annals of Oncology</i> , 2006, 17, 361-371.	1.2	73

#	ARTICLE	IF	CITATIONS
37	Second St. Gallen European Organisation for Research and Treatment of Cancer Gastrointestinal Cancer Conference: consensus recommendations on controversial issues in the primary treatment of rectal cancer. European Journal of Cancer, 2016, 63, 11-24.	2.8	73
38	Primary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features. Radiology, 2017, 284, 552-561.	7.3	66
39	Cetuximab and chemoradiation for rectal cancer—“is the water getting muddy?”. Acta Oncologica, 2010, 49, 278-286.	1.8	64
40	Magnetic Resonance Imaging Assessment of Squamous Cell Carcinoma of the Anal Canal Before and After Chemoradiation: Can MRI Predict for Eventual Clinical Outcome?. International Journal of Radiation Oncology Biology Physics, 2010, 78, 715-721.	0.8	62
41	A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study. British Journal of Cancer, 2005, 93, 993-998.	6.4	61
42	Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers, 2016, 8, 81.	3.7	61
43	The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Annals of Oncology, 2008, 19, vi1-vi8.	1.2	59
44	Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm?. Journal of Clinical Oncology, 2007, 25, 5281-5286.	1.6	58
45	Outcome measures in multimodal rectal cancer trials. Lancet Oncology, The, 2020, 21, e252-e264.	10.7	56
46	A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. British Journal of Cancer, 2007, 96, 551-558.	6.4	51
47	“Mind the Gap”—The Impact of Variations in the Duration of the Treatment Gap and Overall Treatment Time in the First UK Anal Cancer Trial (ACT I). International Journal of Radiation Oncology Biology Physics, 2011, 81, 1488-1494.	0.8	51
48	Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: Systematic review. Critical Reviews in Oncology/Hematology, 2018, 129, 91-101.	4.4	51
49	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. The Lancet Gastroenterology and Hepatology, 2019, 4, 529-537.	8.1	51
50	Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation?. Annals of Oncology, 2012, 23, 2517-2526.	1.2	50
51	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. Lancet Respiratory Medicine, the, 2019, 7, 523-532.	10.7	50
52	A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). Journal of Clinical Oncology, 2009, 27, LBA4009-LBA4009.	1.6	50
53	How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement. Cancer Treatment Reviews, 2020, 84, 101964.	7.7	49
54	To PET or not to PET? That is the question. Staging in anal cancer. Annals of Oncology, 2012, 23, 2078-2082.	1.2	47

#	ARTICLE	IF	CITATIONS
55	Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. <i>Journal of Clinical Oncology</i> , 2006, 24, 3528-3528.	1.6	47
56	Improving Chemoradiotherapy in Rectal Cancer. <i>Oncologist</i> , 2001, 6, 29-34.	3.7	46
57	Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 319-320.	0.8	46
58	The Development of an Umbrella Trial (PLATO) to Address Radiation Therapy Dose Questions in the Locoregional Management of Squamous Cell Carcinoma of the Anus. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, E164-E165.	0.8	46
59	Systematic review of the quality of life issues associated with anal cancer and its treatment with radiochemotherapy. <i>Supportive Care in Cancer</i> , 2015, 23, 3613-3623.	2.2	45
60	Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial. <i>Annals of Oncology</i> , 2014, 25, 1616-1622.	1.2	44
61	Late gastrointestinal toxicity after radiotherapy for anal cancer: a systematic literature review. <i>Acta Oncologica</i> , 2018, 57, 1427-1437.	1.8	44
62	Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. <i>Annals of Oncology</i> , 2020, 31, 1160-1168.	1.2	41
63	Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 1202-1211.	0.8	39
64	Complete Response after Chemoradiotherapy in Rectal Cancer (Watch-and-Wait): Have we Cracked the Code?. <i>Clinical Oncology</i> , 2016, 28, 152-160.	1.4	38
65	Locally Advanced Rectal Cancer: What Is the Evidence for Induction Chemoradiation?. <i>Oncologist</i> , 2007, 12, 1309-1318.	3.7	37
66	Anal Cancer: Developing an Intensity-modulated Radiotherapy Solution for ACT2 Fractionation. <i>Clinical Oncology</i> , 2014, 26, 720-721.	1.4	37
67	Chemotherapy/chemoradiation in anal cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2011, 37, 520-532.	7.7	35
68	Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015. <i>Clinical Oncology</i> , 2017, 29, 188-197.	1.4	35
69	High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. <i>Brachytherapy</i> , 2010, 9, 66-70.	0.5	34
70	Phase III development of the EORTC QLQ-ANL27, a health-related quality of life questionnaire for anal cancer. <i>Radiotherapy and Oncology</i> , 2018, 126, 222-228.	0.6	34
71	Can I Look at My List? An Evaluation of a "Prompt Sheet"™ Within an Oncology Outpatient Clinic. <i>Clinical Oncology</i> , 2006, 18, 395-400.	1.4	33
72	Challenges in the neoadjuvant treatment of rectal cancer: Balancing the risk of recurrence and quality of life. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2013, 17, 675-685.	1.4	33

#	ARTICLE	IF	CITATIONS
73	Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum. <i>BMC Cancer</i> , 2015, 15, 764.	2.6	32
74	Squamous-cell carcinoma of the anus: progress in radiotherapy treatment. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 447-459.	27.6	32
75	Optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4004-4004.	1.6	30
76	Squamous cell carcinoma antigen. <i>Cancer</i> , 2013, 119, 2391-2398.	4.1	28
77	Locally Advanced Rectal Cancer. <i>Drugs</i> , 2011, 71, 1153-1177.	10.9	27
78	Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): Long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin. <i>Radiotherapy and Oncology</i> , 2012, 104, 155-160.	0.6	27
79	Association between pretreatment haemoglobin levels and morphometric characteristics of the tumour, response to neoadjuvant treatment and long-term outcomes in patients with locally advanced rectal cancers. <i>Colorectal Disease</i> , 2013, 15, 1232-1237.	1.4	26
80	UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes. <i>European Journal of Cancer</i> , 2020, 128, 7-16.	2.8	25
81	Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial. <i>Annals of Oncology</i> , 2020, 31, 1376-1385.	1.2	23
82	Clinical endpoints in trials of chemoradiation for patients with anal cancer. <i>Lancet Oncology</i> , The, 2017, 18, e218-e227.	10.7	22
83	The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 264-84.	1.4	22
84	The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal. <i>European Radiology</i> , 2018, 28, 1512-1519.	4.5	21
85	BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). <i>Heliyon</i> , 2018, 4, e00804.	3.2	21
86	Short course continuous, hyperfractionated, accelerated radiation therapy (CHART) as preoperative treatment for rectal cancer. <i>Acta Oncologica</i> , 2006, 45, 1079-1085.	1.8	20
87	Current Treatment of Anal Squamous Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 1315-1350.	2.2	20
88	Multimodal treatment of rectal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 1049-1070.	2.4	19
89	Anal Cancer: An Examination of Radiotherapy Strategies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1290-1301.	0.8	19
90	A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II). <i>Journal of Clinical Oncology</i> , 2009, 27, LBA4009-LBA4009.	1.6	19

#	ARTICLE	IF	CITATIONS
91	Background and Current Treatment of Squamous Cell Carcinoma of the Anus. <i>Oncology and Therapy</i> , 2016, 4, 135-172.	2.6	18
92	The Management and Prevention of Anal Squamous Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 216-225.	3.8	18
93	Clinical target volumes in anal cancer: Calculating what dose was likely to have been delivered in the UK ACT II trial protocol. <i>Radiotherapy and Oncology</i> , 2012, 103, 341-346.	0.6	15
94	MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 119-126.	0.6	15
95	The optimal timing for the interval to surgery after short course preoperative radiotherapy (5 Å–5 Gy) in rectal cancer - are we too eager for surgery?. <i>Cancer Treatment Reviews</i> , 2020, 90, 102104.	7.7	14
96	Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy. <i>International Journal of Colorectal Disease</i> , 2020, 35, 685-694.	2.2	14
97	The pattern and timing of disease recurrence in squamous cancer of the anus: Mature results from the NCRI ACT II trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4029-4029.	1.6	14
98	Treatment of the Primary Tumor in Anal Canal Cancers. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 73-90.	1.5	13
99	Adjuvant chemotherapy for rectal cancer. <i>Annals of Oncology</i> , 2010, 21, 2443.	1.2	12
100	Should we favour the use of 5Å–5 preoperative radiation in rectal cancer. <i>Cancer Treatment Reviews</i> , 2019, 81, 101908.	7.7	12
101	The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. <i>Radiotherapy and Oncology</i> , 2020, 142, 6-16.	0.6	12
102	The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer. <i>Lancet Oncology</i> , The, 2021, 22, e314-e326.	10.7	12
103	Neoadjuvant Treatment in Rectal Cancer: Do We Always Need Radiotherapy“or Can We Risk Assess Locally Advanced Rectal Cancer Better?. <i>Recent Results in Cancer Research</i> , 2012, 196, 21-36.	1.8	12
104	Anal Cancer: Are We Making Progress?. <i>Current Oncology Reports</i> , 2013, 15, 170-181.	4.0	11
105	Anal cancer “ What is the optimum chemoradiotherapy?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2016, 30, 641-653.	2.4	11
106	Interim 18FDG PET/CT during radiochemotherapy in the management of pelvic malignancies: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 28-42.	4.4	11
107	Body Composition and Dose-limiting Toxicity in Colorectal Cancer Chemotherapy Treatment; a Systematic Review of the Literature. Could Muscle Mass be the New Body Surface Area in Chemotherapy Dosing?. <i>Clinical Oncology</i> , 2021, 33, e540-e552.	1.4	11
108	Prevalence of nodal involvement in rectal cancer after chemoradiotherapy. <i>British Journal of Surgery</i> , 2021, 108, 1251-1258.	0.3	11

#	ARTICLE	IF	CITATIONS
109	ARISTOTLE: A phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC).. Journal of Clinical Oncology, 2020, 38, 4101-4101.	1.6	11
110	Antiepidermal growth factor receptor radiosensitizers in rectal cancer. Anti-Cancer Drugs, 2011, 22, 330-340.	1.4	10
111	Optimal management of localized rectal cancer in older patients. Journal of Geriatric Oncology, 2018, 9, 696-704.	1.0	10
112	Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first?. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591878799.	3.2	10
113	Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer. Clinics in Colon and Rectal Surgery, 2020, 33, 287-297.	1.1	10
114	Anal Cancer: The End of the Road for Neoadjuvant Chemoradiotherapy?. Journal of Clinical Oncology, 2008, 26, 3669-3671.	1.6	9
115	Rectal cancer – the times they are a-changing. Lancet Oncology, The, 2012, 13, 651-653.	10.7	9
116	Multimodal Rectal Cancer Treatment: In Some Cases, Less May Be More. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 92-102.	3.8	9
117	Pooled Analysis of external-beam Radiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). European Journal of Cancer, 2019, 121, 130-143.	2.8	9
118	A Pilot Study of Continuous, Hyperfractionated, Accelerated Radiotherapy in Rectal Adenocarcinoma. Clinical Oncology, 1999, 11, 334-339.	1.4	8
119	Chemotherapy or No Chemotherapy in Clear Margins after Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: CHRONICLE. A Randomised Phase III Trial of Control vs. Capecitabine plus Oxaliplatin. Clinical Oncology, 2007, 19, 327-329.	1.4	8
120	Chemoradiotherapy in anal cancer. Colorectal Disease, 2011, 13, 33-38.	1.4	8
121	Role of Neoadjuvant Chemotherapy in Rectal Cancer: Interpretation of the EXPERT Study. Journal of Clinical Oncology, 2006, 24, 4664-4665.	1.6	7
122	Neoadjuvant therapy before surgical treatment. European Journal of Cancer, Supplement, 2013, 11, 45-59.	2.2	7
123	Radiotherapy and locally advanced rectal cancer. British Journal of Surgery, 2015, 102, 1443-1445.	0.3	7
124	Do T3 Rectal Cancers Always Need Radiochemotherapy?. Recent Results in Cancer Research, 2014, 203, 95-115.	1.8	7
125	Suppression of the postoperative neutrophil leucocytosis following neoadjuvant chemoradiotherapy for rectal cancer and implications for surgical morbidity. Colorectal Disease, 2010, 12, 549-554.	1.4	6
126	Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: One size does not fit all. Annals of Oncology, 2015, 26, 617-619.	1.2	6

#	ARTICLE	IF	CITATIONS
127	Identification of Cancer-Associated Circulating Cells in Anal Cancer Patients. <i>Cancers</i> , 2020, 12, 2229.	3.7	6
128	Neoadjuvant short-course radiotherapy with consolidation chemotherapy for locally advanced rectal cancer: a systematic review and meta-analysis. <i>Acta Oncol</i> gica, 2021, 60, 1308-1316.	1.8	6
129	Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC). <i>Journal of Clinical Oncology</i> , 2004, 22, 3575-3575.	1.6	6
130	Radiotherapy and oncology. <i>Radiotherapy and Oncology</i> , 2012, 102, 161-162.	0.6	5
131	Early rectal cancer: opening the door to change. <i>Lancet Oncology</i> , The, 2015, 16, 1449-1451.	10.7	5
132	Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT. <i>Medical Oncology</i> , 2018, 35, 59.	2.5	5
133	Watch and wait in rectal cancer: is it time to subclassify cT3?. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 814-815.	8.1	5
134	TNT in rectal cancer may not be the new testament?. <i>EClinicalMedicine</i> , 2019, 16, 4-5.	7.1	5
135	USPIO ? enhanced rectal cancer specimen MRI: how well does it correlate with node identification at histopathology?. <i>Colorectal Disease</i> , 2006, 8, 721-721.	1.4	4
136	Capturing Data on Colostomy Formation in Anal Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 164-164.	1.6	4
137	End Points in Anal Cancer: Hopes for a Common Language. <i>Journal of Clinical Oncology</i> , 2014, 32, 1281-1282.	1.6	4
138	The D Prefix. <i>Diseases of the Colon and Rectum</i> , 2015, 58, 613-616.	1.3	4
139	Preoperative radiotherapy for locally advanced rectal cancer during and after the COVID-19 pandemic. <i>British Journal of Surgery</i> , 2020, 107, e263-e263.	0.3	4
140	The Evolving Neoadjuvant Treatment Paradigm for Patients with Locoregional mismatch Repair Proficient Rectal Cancer. <i>Current Treatment Options in Oncology</i> , 2022, 23, 453-473.	3.0	4
141	First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. <i>British Journal of Cancer</i> , 2022, 126, 1548-1554.	6.4	4
142	Optimal Sequencing of Neoadjuvant Therapies (NAT) in Rectal Cancer: Upfront Chemotherapy vs. Upfront Chemoradiation. <i>Current Colorectal Cancer Reports</i> , 2017, 13, 154-164.	0.5	3
143	Looking for the Good, Bad and the Ugly rectal cancers of the twenty-first centuryâ€ or â€œHow to avoid tears when peeling onionsâ€€. <i>Techniques in Coloproctology</i> , 2017, 21, 577-579.	1.8	3
144	FOLFOXIRI reintroduction in metastatic colorectal cancer. <i>Lancet Oncology</i> , The, 2020, 21, 468-469.	10.7	3

#	ARTICLE	IF	CITATIONS
145	Interpreting the RAPIDO trial: factors to consider. Lancet Oncology, The, 2021, 22, e85.	10.7	3
146	Anal cancer: is neoadjuvant cisplatin chemotherapy or chemoradiotherapy friend or foe?. Nature Clinical Practice Oncology, 2008, 5, 692-693.	4.3	2
147	Or why translational research is vital for the future treatment of rectal cancer. Clinical and Translational Oncology, 2011, 13, 701-702.	2.4	2
148	What is the Impact of the Addition of Oxaliplatin to 5-Fluorouracil-Based Preoperative Chemoradiation in Rectal Cancer?. Current Colorectal Cancer Reports, 2011, 7, 1-4.	0.5	1
149	Commentary on Latkauskas et al... Colorectal Disease, 2012, 14, 299-301.	1.4	1
150	Drug Combinations in Preoperative Chemoradiation for Rectal Cancer. Seminars in Radiation Oncology, 2016, 26, 211-219.	2.2	1
151	Cetuximab in the Context of Current Treatment of Squamous Cell Carcinoma of the Anus. Journal of Clinical Oncology, 2017, 35, 699-701.	1.6	1
152	Current Status of the Watch-and-Wait Policy for Patients with Complete Clinical Response Following Neoadjuvant Chemoradiation in Rectal Cancer. Current Colorectal Cancer Reports, 2017, 13, 17-26.	0.5	1
153	Adding extra dimensions in rectal cancer theory. Annals of Oncology, 2017, 28, 198-200.	1.2	1
154	Session 4: What should we do for poor responders after chemoradiotherapy: bad biology or should the fight go on?. Colorectal Disease, 2018, 20, 97-99.	1.4	1
155	Extending the interval to surgery in rectal cancer and filling the time with chemotherapy—how much is enough?. Annals of Oncology, 2019, 30, 1188-1190.	1.2	1
156	Reply to the letter to the editor: DPD testing in radical chemoradiation for anal squamous cell carcinoma? by R. Muirhead, H. Jones, D. Gilbert, A. Gilbert & C. Jacobs. Annals of Oncology, 2020, 31, 1587-1588.	1.2	1
157	Compliance to chemoradiation in squamous cell carcinoma of the anus. Cancer Treatment Reviews, 2022, 106, 102381.	7.7	1
158	Is the timing of chemotherapy important in patients undergoing preoperative radiotherapy for rectal cancer?. Nature Clinical Practice Oncology, 2007, 4, 150-151.	4.3	0
159	Are there alternatives to radical surgery in rectal cancer?. Current Colorectal Cancer Reports, 2009, 5, 240-246.	0.5	0
160	Anal Cancer. , 2011, , 423-450.		0
161	and a two-edged sword in their hands. Lancet Oncology, The, 2011, 12, 519-520.	10.7	0
162	One Size Does Not Fit All: Planning Volumes for Radiotherapy in Rectal Cancer—Should We Tailor Radiotherapy Fields to Stage and Risk?. Current Colorectal Cancer Reports, 2011, 7, 89-96.	0.5	0

#	ARTICLE	IF	CITATIONS
163	Colorectal Cancer in the Elderly: How Do We Tailor Treatment with Chemotherapy and Radiotherapy Most Appropriately?. Current Colorectal Cancer Reports, 2013, 9, 146-156.	0.5	0
164	Current Evidence for Chemotherapy, Chemoradiation, and the Liver-First Approach for the Management of Patients With Rectal Cancer and Synchronous Liver Metastases. Current Colorectal Cancer Reports, 2014, 10, 147-156.	0.5	0
165	How Should a Multi-disciplinary Team (MDT) Approach the Issue of Non-Operative Management in Rectal Cancer?. Current Colorectal Cancer Reports, 2015, 11, 352-359.	0.5	0
166	PARP inhibitors and chemoradiation for rectal cancer. The Lancet Gastroenterology and Hepatology, 2017, 2, 389-390.	8.1	0
167	NICE guideline for rectal cancer: already out of date. Lancet, The, 2020, 395, e105-e106.	13.7	0
168	Unintended consequences of treating early rectal cancers for complete clinical response with chemoradiotherapy. Colorectal Cancer, 2020, 9, .	0.8	0
169	Radiation Therapy in Anal Cancer. , 2018, , 1-23.		0
170	Chemotherapy and Biologic Therapy in Rectal Cancer: An Update. , 2019, , 407-444.		0
171	Chemoradiotherapy for Locally Advanced T3/T4 Rectal Cancer: What Should We Do with Complete Responders?. , 2021, , 203-222.		0
172	Compliance to chemotherapy with oxaliplatin and 5 fluorouracil in patients with advanced rectal cancer who have received prior high-dose pelvic radiotherapy. Journal of Clinical Oncology, 2004, 22, 3747-3747.	1.6	0